Table 1

Schedule of clinical events

Assessments/Procedures
(weeks)		ScreenW2
#1		W4
#2		W6
#3		W8
#4		W10
#5		W12
#6		W14W16W26W52
Written informed consent/HIPPAX          
Inclusion/Exclusion criteriaX          
Baseline medical history and physical examinationX          
Physical examinationXXXXXXX    
Interim history XXXXXX  XX
Toxicity assessment, adverse experiences, modified Rankin scoreXXXXXXXXXXX
NIH Stroke Scale, Neuro-QoL QuestionnaireX     X  XX
ECGX          
Administer study drug XXXXXX    
Laboratory evaluation (plasma angiogenic/inflammatory markers): VEGF, FGF2, CRP, ESR, IL-1, IL-2, IL-6, MPO, TNF-αX     X  XX
Laboratory evaluations*: complete blood count with differential, creatinine, blood urea nitrogen, liver function tests, prothrombin time, partial thromboplastin timeXXXXXXX  XX
Laboratory evaluations*: urine protein/creatinine ratio (urine dipstick for protein prior to infusions)X X X X    
MRIX        XX
Pregnancy test (if applicable)X        XX

  • *Completed within 3 days of bevacizumab infusion when applicable.

  • CRP, C reactive protein; ESR, erythrocyte sedimentation rate; FGF2, fibroblast growth factor 2; IL, interleukin; MPO, myeloperoxidase; Neuro-QoL, Quality of Life in Neurologic Disorders; NIH, National Institutes of Health; TNF-α, tumour necrosis factor α; VEGF, vascular endothelial growth factor.